I-Mab - ADR

Name: I-Mab - ADR Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: I-Mab - ADR

Stock Card

$3.98

$0.02 (0.51%)

As on 31-Dec-2025 09:30EDT

Market cap

$534 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

1.8

Div. Yield

0 %

I-Mab - ADR Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 3.90 High: 4.06

52 Week Range

Low: 0.60 High: 6.79

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.2 %
ROCE

-- %
Industry P/E

37.32
EV/EBITDA

0.1
Debt to Equity

0
Book Value

$--
EPS

$-0.2
Face value

--
Shares outstanding

115,266,053

7 Years Aggregate

CFO

$-4,348.13 Mln

EBITDA

$-7,553.29 Mln

Net Profit

$-7,894.06 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
I-Mab - ADR	368.2	3.6	16.4	352.3	-1.6	-37.7	--
BSE Sensex^*	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 31-Dec-2025 | *As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022	2021
I-Mab - ADR	365.9	-55.0	-54.5	-91.2	0.5
S&P Small-Cap 600	4.0	7.0	13.9	-17.4	25.3
BSE Sensex	9.1	8.1	18.7	4.4	22.0

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
I-Mab - ADR	4.0	533.7	0.0	-24.5	--	-10.7	--	1.8
Amneal Pharmaceuticals Inc Class A (AMRX)	17.5	6,109.1	3,117.6	157.4	14.7	--	37.3	190.1
Axsome Therapeutics (AXSM)	199.0	10,424.8	776.6	-191.6	-17.6	-223.4	--	129.6
BridgeBio Pharma (BBIO)	76.6	14,974.8	691.8	-696.2	-89.1	--	--	123.7
Corcept Therapeutics (CORT)	113.9	12,310.3	830.8	54.9	3.2	8.1	264.8	17.9
Elanco Animal Health (ELAN)	24.1	11,971.8	5,020.0	-199.0	1.6	-3	--	1.8
Grifols S.A. - ADR	7.7	5,233.7	7,430.4	452.5	17.6	7	10	0.8
Ligand Pharmaceuticals (LGND)	280.5	5,591.7	290.5	197.2	82.5	19.9	28.9	5.9
Liquidia Technologies Inc (LQDA)	67.7	6,058.9	450.9	138.6	39.1	115.6	50.1	32.1
Twist Bioscience Corp (TWST)	141.4	8,865.6	431.8	-136.7	-30.8	-30.3	--	21.5

Shareholding Pattern

View Details

About I-Mab - ADR

I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of... gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland. Read more

CEO & Director

Mr. Raj Kannan
Chief Financial Officer

Mr. Skelton Joseph
Headquarters

Rockville, MD
Website

https://www.i-mabbiopharma.com

FAQs for I-Mab - ADR

What is the current share price of I-Mab - ADR Today?

The share price of I-Mab - ADR is $3.98 (NASDAQ) as of 31-Dec-2025 09:30 EDT. I-Mab - ADR has given a return of -1.62% in the last 3 years.

What is the current PB & PE ratio of I-Mab - ADR?

Since, TTM earnings of I-Mab - ADR is negative, P/E ratio is not available.
The P/B ratio of I-Mab - ADR is 1.76 times as on 31-Dec-2025, a 77 discount to its peers’ median range of 7.75 times.

PE & PB ratio at the end of financial year.